BioAtla, Inc. BCAB

BCAB Company Overview

BioAtla, Inc. is a clinical-stage biotechnology company focused on developing antibody-based therapeutics for cancer treatment. The company operates within the oncology and biopharmaceutical industries and is best known for its proprietary Conditionally Active Biologics (CAB) platform, which is designed to activate therapeutic antibodies selectively within the tumor microenvironment while remaining relatively inactive in normal tissue. BioAtla’s primary revenue sources have historically consisted of collaboration agreements, licensing arrangements, and research funding, as the company has not yet commercialized an approved product based on publicly available filings. Its development pipeline has included antibody-drug conjugates and monoclonal antibodies targeting solid tumors and hematologic malignancies.

The company was founded in 2007 and is headquartered in San Diego, California. BioAtla evolved from an early-stage antibody engineering company into a clinical-stage oncology developer through investments in its CAB technology platform and expansion of its therapeutic pipeline. The company has emphasized differentiated tumor-selective biologics intended to improve efficacy and safety compared with conventional antibody therapies. Public disclosures, including SEC filings and investor presentations, identify BioAtla’s strategic positioning as centered on precision oncology and next-generation antibody engineering.